Fedratinib Induces Nonclassical G2–M Arrest via Mitotic Kinase Inhibition and Synergizes with Mitomycin C to Suppress Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics · Published 2026-07-13 · DOI 10.1158/1535-7163.mct-26-0137

Authors (2)

Hui-Ying Li, Pei-Ming Yang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Li, H., Yang, P. (2026). Fedratinib Induces Nonclassical G2–M Arrest via Mitotic Kinase Inhibition and Synergizes with Mitomycin C to Suppress Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-26-0137

Related articles